| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
|
N Engl J Med
|
2005
|
33.60
|
|
2
|
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
|
J Clin Oncol
|
2011
|
4.81
|
|
3
|
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
|
J Clin Oncol
|
2006
|
4.55
|
|
4
|
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
|
J Clin Oncol
|
2008
|
4.24
|
|
5
|
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.
|
J Natl Cancer Inst
|
2002
|
3.34
|
|
6
|
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
|
J Clin Oncol
|
2011
|
3.02
|
|
7
|
Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve.
|
J Clin Oncol
|
2010
|
2.52
|
|
8
|
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
|
J Clin Oncol
|
2010
|
2.49
|
|
9
|
Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes.
|
Radiology
|
2009
|
2.45
|
|
10
|
Image-guided optical spectroscopy provides molecular-specific information in vivo: MRI-guided spectroscopy of breast cancer hemoglobin, water, and scatterer size.
|
Opt Lett
|
2007
|
2.34
|
|
11
|
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
|
J Clin Oncol
|
2013
|
2.15
|
|
12
|
Cognitive function in breast cancer patients prior to adjuvant treatment.
|
Breast Cancer Res Treat
|
2007
|
1.95
|
|
13
|
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
|
Clin Cancer Res
|
2011
|
1.78
|
|
14
|
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
|
Lancet Oncol
|
2013
|
1.77
|
|
15
|
Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
|
Clin Breast Cancer
|
2010
|
1.41
|
|
16
|
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
|
Breast Cancer Res Treat
|
2014
|
1.32
|
|
17
|
In vivo quantitative imaging of normal and cancerous breast tissue using broadband diffuse optical tomography.
|
Med Phys
|
2010
|
1.23
|
|
18
|
Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.
|
J Oncol Pract
|
2010
|
1.22
|
|
19
|
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
|
J Clin Oncol
|
2011
|
1.21
|
|
20
|
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
|
J Clin Oncol
|
2004
|
1.16
|
|
21
|
Tumor angiogenesis change estimated by using diffuse optical spectroscopic tomography: demonstrated correlation in women undergoing neoadjuvant chemotherapy for invasive breast cancer?
|
Radiology
|
2011
|
1.14
|
|
22
|
Fast 3-d tomographic microwave imaging for breast cancer detection.
|
IEEE Trans Med Imaging
|
2012
|
1.13
|
|
23
|
Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
|
Breast Cancer Res Treat
|
2014
|
1.10
|
|
24
|
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
|
Cancer
|
2013
|
1.06
|
|
25
|
Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience.
|
Breast Cancer Res
|
2013
|
1.05
|
|
26
|
Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment.
|
Int J Hyperthermia
|
2013
|
1.00
|
|
27
|
Developments in quantitative oxygen-saturation imaging of breast tissue in vivo using multispectral near-infrared tomography.
|
Antioxid Redox Signal
|
2007
|
0.88
|
|
28
|
First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
|
Oncologist
|
2013
|
0.88
|
|
29
|
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
|
Cancer Treat Rev
|
2008
|
0.85
|
|
30
|
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
|
BMC Cancer
|
2014
|
0.84
|
|
31
|
Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking.
|
Psychooncology
|
2014
|
0.84
|
|
32
|
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.
|
Clin Cancer Res
|
2013
|
0.82
|
|
33
|
Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective.
|
Breast Cancer Res Treat
|
2008
|
0.81
|
|
34
|
Pilot study assessment of dynamic vascular changes in breast cancer with near-infrared tomography from prospectively targeted manipulations of inspired end-tidal partial pressure of oxygen and carbon dioxide.
|
J Biomed Opt
|
2013
|
0.79
|
|
35
|
Development and initial evaluation of a telephone-delivered, behavioral activation, and problem-solving treatment program to address functional goals of breast cancer survivors.
|
J Psychosoc Oncol
|
2015
|
0.78
|
|
36
|
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer.
|
Breast Cancer Res Treat
|
2013
|
0.77
|
|
37
|
Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
|
Breast Cancer Res Treat
|
2015
|
0.77
|
|
38
|
The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer.
|
Cancer Chemother Pharmacol
|
2002
|
0.76
|
|
39
|
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
|
Breast Cancer Res Treat
|
2012
|
0.76
|
|
40
|
HER2-positive breast cancer: the story goes on.
|
Oncology (Williston Park)
|
2014
|
0.75
|
|
41
|
Real-time electrical impedance variations in women with and without breast cancer.
|
IEEE Trans Med Imaging
|
2014
|
0.75
|
|
42
|
Microwave tomography in the context of complex breast cancer imaging.
|
Conf Proc IEEE Eng Med Biol Soc
|
2010
|
0.75
|
|
43
|
Image guided near-infrared spectroscopy of breast tissue in vivo using boundary element method.
|
J Biomed Opt
|
2011
|
0.75
|